LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article ; Online: Intermediate and long-term outcomes of a bowel management program for children with severe constipation or fecal incontinence.

    Kilpatrick, Julie A / Zobell, Sarah / Leeflang, Elisabeth J / Cao, Duyen / Mammen, Lija / Rollins, Michael D

    Journal of pediatric surgery

    2019  Volume 55, Issue 3, Page(s) 545–548

    Abstract: Purpose: We sought to examine the long-term clinical success rates of a bowel management program (BMP) for children with severe constipation or fecal incontinence.: Methods: A single center review was conducted of children (≤18 years) enrolled in a ... ...

    Abstract Purpose: We sought to examine the long-term clinical success rates of a bowel management program (BMP) for children with severe constipation or fecal incontinence.
    Methods: A single center review was conducted of children (≤18 years) enrolled in a BMP and followed in a colorectal specialty clinic (2011-2017). All patients who completed an initial week of the BMP were included. Patients enrolled in a BMP after 2018 were excluded. Success was defined as no accidents and <2 stool smears per week.
    Results: A total of 285 patients were reviewed. BMP was initiated at a median age of 7 years (9 months-17 years). Primary diagnoses included functional constipation (112), anorectal malformation (ARM) (104), Hirschsprung Disease (HD) (41), rectal prolapse (14), spina bifida (6), fecal incontinence (3) and other (5; 4 sacral coccygeal teratomas and a GSW to the buttocks). Initial bowel regimen included large volume enema in 54% and high dose stimulant laxative in 46%. The initial Bowel Management Week (BMW) was successful in 233 (87% of adherent patients) patients with 17 (6%) non-adherent. One hundred twenty-two patients had follow-up at 12 months (72% success amongst adherent patients, 7% of patient non-adherent) and 98 patients had follow-up at 24 months (78% success amongst adherent patients, 10% of patients non-adherent). 21/154 (14%) patients started on enemas were later successfully transitioned to laxatives and 13/132 (10%) patients started on laxatives subsequently required enemas in order to stay clean. Clinic phone contact occurred outside of scheduled visits for adjustment to the BMP in 44% of patients. 33% of patients had surgery to aid bowel management (antegrade colonic enema (ACE) = 81, resection + ACE = 13, diverting stoma = 4). Median follow up was 2.5 years (5 weeks-7 years).
    Conclusion: Children who follow a structured BMP with readily available personnel to provide outpatient assistance can experience successful treatment of severe constipation or fecal incontinence long-term. A multi-institutional collaboration is necessary to identify factors which predict failure of a BMP and non-adherence.
    Type of study: Single-center retrospective chart review.
    Level of evidence: 3.
    MeSH term(s) Adolescent ; Child ; Child, Preschool ; Constipation/epidemiology ; Constipation/therapy ; Enema/statistics & numerical data ; Fecal Incontinence/epidemiology ; Fecal Incontinence/therapy ; Hirschsprung Disease ; Humans ; Infant ; Laxatives/therapeutic use ; Rectal Prolapse ; Retrospective Studies ; Treatment Outcome
    Chemical Substances Laxatives
    Language English
    Publishing date 2019-11-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80165-3
    ISSN 1531-5037 ; 0022-3468
    ISSN (online) 1531-5037
    ISSN 0022-3468
    DOI 10.1016/j.jpedsurg.2019.10.062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

    Brown, Christine E / Hibbard, Jonathan C / Alizadeh, Darya / Blanchard, M Suzette / Natri, Heini M / Wang, Dongrui / Ostberg, Julie R / Aguilar, Brenda / Wagner, Jamie R / Paul, Jinny A / Starr, Renate / Wong, Robyn A / Chen, Wuyang / Shulkin, Noah / Aftabizadeh, Maryam / Filippov, Aleksandr / Chaudhry, Ammar / Ressler, Julie A / Kilpatrick, Julie /
    Myers-McNamara, Paige / Chen, Mike / Wang, Leo D / Rockne, Russell C / Georges, Joseph / Portnow, Jana / Barish, Michael E / D'Apuzzo, Massimo / Banovich, Nicholas E / Forman, Stephen J / Badie, Behnam

    Nature medicine

    2024  

    Language English
    Publishing date 2024-03-21
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02928-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

    Brown, Christine E / Hibbard, Jonathan C / Alizadeh, Darya / Blanchard, M Suzette / Natri, Heini M / Wang, Dongrui / Ostberg, Julie R / Aguilar, Brenda / Wagner, Jamie R / Paul, Jinny A / Starr, Renate / Wong, Robyn A / Chen, Wuyang / Shulkin, Noah / Aftabizadeh, Maryam / Filippov, Aleksandr / Chaudhry, Ammar / Ressler, Julie A / Kilpatrick, Julie /
    Myers-McNamara, Paige / Chen, Mike / Wang, Leo D / Rockne, Russell C / Georges, Joseph / Portnow, Jana / Barish, Michael E / D'Apuzzo, Massimo / Banovich, Nicholas E / Forman, Stephen J / Badie, Behnam

    Nature medicine

    2024  Volume 30, Issue 4, Page(s) 1001–1012

    Abstract: Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2- ... ...

    Abstract Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration (intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV) and two manufacturing platforms, culminating in arm 5, which utilized dual ICT/ICV delivery and an optimized manufacturing process. Locoregional CAR-T cell administration was feasible and well tolerated, and as there were no dose-limiting toxicities across all arms, a maximum tolerated dose was not determined. Probable treatment-related grade 3+ toxicities were one grade 3 encephalopathy and one grade 3 ataxia. A clinical maximum feasible dose of 200 × 10
    MeSH term(s) Humans ; Receptors, Chimeric Antigen ; Neoplasm Recurrence, Local ; Glioma/therapy ; T-Lymphocytes ; Glioblastoma/therapy ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02875-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Loneliness Curriculum of Psychiatric Training.

    Katzman, Jeffrey / Geppert, Cynthia / Kilpatrick, Julie / Graeber, David / Arenella, Pamela B

    Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry

    2016  Volume 40, Issue 1, Page(s) 111–116

    MeSH term(s) Confidentiality ; Curriculum ; Humans ; Internship and Residency/methods ; Interpersonal Relations ; Loneliness/psychology ; Mental Disorders/therapy ; Psychiatry/education
    Language English
    Publishing date 2016-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1045331-3
    ISSN 1545-7230 ; 1042-9670
    ISSN (online) 1545-7230
    ISSN 1042-9670
    DOI 10.1007/s40596-015-0461-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Predicting ICU readmission among surgical ICU patients: Development and validation of a clinical nomogram.

    Martin, Luke A / Kilpatrick, Julie A / Al-Dulaimi, Ragheed / Mone, Mary C / Tonna, Joseph E / Barton, Richard G / Brooke, Benjamin S

    Surgery

    2018  Volume 165, Issue 2, Page(s) 373–380

    Abstract: Background: Unplanned intensive care unit readmission within 72 hours is an established metric of hospital care quality. However, it is unclear what factors commonly increase the risk of intensive care unit readmission in surgical patients. The ... ...

    Abstract Background: Unplanned intensive care unit readmission within 72 hours is an established metric of hospital care quality. However, it is unclear what factors commonly increase the risk of intensive care unit readmission in surgical patients. The objective of this study was to evaluate predictors of readmission among a diverse sample of surgical patients and develop an accurate and clinically applicable nomogram for prospective risk prediction.
    Methods: We retrospectively evaluated patient demographic characteristics, comorbidities, and physiologic variables collected within 48 hours before discharge from a surgical intensive care unit at an academic center between April 2010 and July 2015. Multivariable regression models were used to assess the association between risk factors and unplanned readmission back to the intensive care unit within 72 hours. Model selection was performed using lasso methods and validated using an independent data set by receiver operating characteristic area under the curve analysis. The derived nomogram was then prospectively assessed between June and August 2017 to evaluate the correlation between perceived and calculated risk for intensive care unit readmission.
    Results: Among 3,109 patients admitted to the intensive care unit by general surgery (34%), transplant (9%), trauma (43%), and vascular surgery (14%) services, there were 141 (5%) unplanned readmissions within 72 hours. Among 179 candidate predictor variables, a reduced model was derived that included age, blood urea nitrogen, serum chloride, serum glucose, atrial fibrillation, renal insufficiency, and respiratory rate. These variables were used to develop a clinical nomogram, which was validated using 617 independent admissions, and indicated moderate performance (area under the curve: 0.71). When prospectively assessed, intensive care unit providers' perception of respiratory risk was moderately correlated with calculated risk using the nomogram (ρ: 0.44; P < .001), although perception of electrolyte abnormalities, hyperglycemia, renal insufficiency, and risk for arrhythmias were not correlated with measured values.
    Conclusion: Intensive care unit readmission risk for surgical patients can be predicted using a simple clinical nomogram based on 7 common demographic and physiologic variables. These data underscore the potential of risk calculators to combine multiple risk factors and enable a more accurate risk assessment beyond perception alone.
    MeSH term(s) Atrial Fibrillation/epidemiology ; Blood Glucose/analysis ; Blood Urea Nitrogen ; Chlorides/blood ; Female ; Hospital Mortality ; Humans ; Intensive Care Units ; Male ; Middle Aged ; Multivariate Analysis ; Nomograms ; Patient Readmission ; Prospective Studies ; Renal Insufficiency, Chronic/epidemiology ; Respiratory Rate ; Retrospective Studies ; Risk Assessment/methods
    Chemical Substances Blood Glucose ; Chlorides
    Language English
    Publishing date 2018-08-29
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Validation Studies
    ZDB-ID 202467-6
    ISSN 1532-7361 ; 0039-6060
    ISSN (online) 1532-7361
    ISSN 0039-6060
    DOI 10.1016/j.surg.2018.06.053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients.

    Portnow, Jana / Badie, Behnam / Suzette Blanchard, M / Kilpatrick, Julie / Tirughana, Revathiswari / Metz, Marianne / Mi, Shu / Tran, Vivi / Ressler, Julie / D'Apuzzo, Massimo / Aboody, Karen S / Synold, Timothy W

    Cancer gene therapy

    2020  Volume 28, Issue 3-4, Page(s) 294–306

    Abstract: Neural stem cells (NSCs) are tumor tropic and can be genetically modified to produce anti-cancer therapies locally in the brain. In a prior first-in-human study we demonstrated that a single dose of intracerebrally administered allogeneic NSCs, which ... ...

    Abstract Neural stem cells (NSCs) are tumor tropic and can be genetically modified to produce anti-cancer therapies locally in the brain. In a prior first-in-human study we demonstrated that a single dose of intracerebrally administered allogeneic NSCs, which were retrovirally transduced to express cytosine deaminase (CD), tracked to glioma sites and converted oral 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU). The next step in the clinical development of this NSC-based anti-cancer strategy was to assess the feasibility of administering multiple intracerebral doses of CD-expressing NSCs (CD-NSCs) in patients with recurrent high-grade gliomas. CD-NSCs were given every 2 weeks using an indwelling brain catheter, followed each time by a 7-d course of oral 5-FC (and leucovorin in the final patient cohort). Fifteen evaluable patients received a median of 4 (range 2-10) intracerebral CD-NSC doses; doses were escalated from 50 × 10
    MeSH term(s) Feasibility Studies ; Genetic Therapy/methods ; Glioma/drug therapy ; Humans ; Neural Stem Cells/transplantation
    Language English
    Publishing date 2020-09-08
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 1212513-1
    ISSN 1476-5500 ; 0929-1903
    ISSN (online) 1476-5500
    ISSN 0929-1903
    DOI 10.1038/s41417-020-00219-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis.

    Wang, Leo / Oill, Angela Taravella / Blanchard, M / Wu, Melody / Hibbard, Jonathan / Sepulveda, Sean / Peter, Lance / Kilpatrick, Julie / Munoz, Margarita / Stiller, Tracey / Shulkin, Noah / Wagner, Jamie / Dolatabadi, Ally / Nisis, Monica / Shepphird, Jennifer / Sanchez, Gabriela / Lingaraju, Chetan / Manchanda, Mishika / Natri, Heini /
    Kouakanou, Léonce / Sun, Grace / Oliver-Cervantes, Cheryl / Georges, Joseph / Aftabizadeh, Maryam / Forman, Stephen / Priceman, Saul / Ressler, Julie / Arvanitis, Leonidas / Cotter, Jennifer / D'Apuzzo, Massimo / Tamrazi, Benita / Badie, Behnam / Davidson, Tom / Banovich, Nicholas / Brown, Christine

    Research square

    2023  

    Abstract: Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I ...

    Abstract Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I clinical trial (NCT04510051) of IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles, identifying clonal expansion of endogenous CAR-negative CD8
    Language English
    Publishing date 2023-10-23
    Publishing country United States
    Document type Preprint
    DOI 10.21203/rs.3.rs-3454977/v1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid.

    Portnow, Jana / Wang, Dongrui / Blanchard, M Suzette / Tran, Vivi / Alizadeh, Darya / Starr, Renate / Dodia, Ramsinh / Chiu, Vivian / Brito, Alfonso / Kilpatrick, Julie / McNamara, Paige / Forman, Stephen J / Badie, Behnam / Synold, Timothy W / Brown, Christine E

    JAMA oncology

    2020  Volume 6, Issue 12, Page(s) 1947–1951

    Abstract: Importance: Little is known about the penetration and bioactivity of systemically administered programmed cell death 1 (PD-1) antibodies in the central nervous system. Such information is critical for advancing checkpoint antibody therapies for ... ...

    Abstract Importance: Little is known about the penetration and bioactivity of systemically administered programmed cell death 1 (PD-1) antibodies in the central nervous system. Such information is critical for advancing checkpoint antibody therapies for treatment of brain tumors.
    Objective: To evaluate pembrolizumab concentrations and PD-1 blockade on T cells in the cerebrospinal fluid (CSF) after intravenous administration.
    Design, setting, and participants: Cerebrospinal fluid and blood samples were collected from 10 adult patients with high-grade gliomas who were participating in clinical trials of intracranially administered chimeric antigen receptor (CAR) T cells and intravenous pembrolizumab at City of Hope in Duarte, California, from 2017 through 2019. Neuropharmacokinetic and immunologic correlative studies were performed on CSF and serum samples.
    Interventions or exposures: Pembrolizumab, 200 mg, was given intravenously every 3 weeks with a median of 2 cycles (range, 1-8). CAR T cells were administered intracranially every 1 to 4 weeks. Cerebrospinal fluid and blood samples were collected on the day of CAR T-cell administration and then 24 hours later for a total of 100 paired samples.
    Main outcomes and measures: Pembrolizumab concentrations were measured by enzyme-linked immunosorbent assay, PD-1 blocking on T cells by flow cytometry, and results of PD-1 blockade on CAR T-cell function by in vitro tumor rechallenge assays.
    Results: Of the 10 patients included in this study, the mean (SD) age was 45.7 (11.0) years, and 6 (60%) were women. Steady-state pembrolizumab concentrations in the CSF were achieved by 24 hours after initial intravenous administration, with a mean CSF:serum ratio of 0.009 (95% CI, 0.004-0.014). The CSF concentrations of pembrolizumab effectively blocked PD-1 on both endogenous T cells and intracranially administered CAR T cells in the CSF, with flow cytometric detection of surface PD-1 on the T cells decreasing from a mean (SD) of 39.3% (20.2%) before pembrolizumab to a mean (SD) of 3.8% (5.8%) 24 hours after pembrolizumab infusion. Steady-state concentrations in the CSF were maintained throughout the 21-day cycle of pembrolizumab, as was the PD-1 blocking effect, evidenced by no increase in detectable surface PD-1 on T cells in the CSF during that time period. Incubation of PD-1-expressing T cells with CSF samples from patients treated with pembrolizumab also resulted in PD-1 blockade.
    Conclusions and relevance: Results of this study demonstrate steady-state concentrations of pembrolizumab in CSF after intravenous administration as well as CSF concentrations that are sufficient for blocking PD-1 on endogenous and adoptively transferred T cells. This provides mechanistic insight regarding the ability of systemically administered PD-1 blocking antibodies to modulate T-cell activity in the brain.
    MeSH term(s) Female ; Humans ; Immunotherapy/methods ; Lymphocyte Count ; Neoplasms ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes
    Chemical Substances Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2020-10-08
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2020.4508
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

    Hardwick, Nicola R / Frankel, Paul / Ruel, Christopher / Kilpatrick, Julie / Tsai, Weimin / Kos, Ferdynand / Kaltcheva, Teodora / Leong, Lucille / Morgan, Robert / Chung, Vincent / Tinsley, Raechelle / Eng, Melissa / Wilczynski, Sharon / Ellenhorn, Joshua D I / Diamond, Don J / Cristea, Mihaela

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2018  Volume 24, Issue 6, Page(s) 1315–1325

    Abstract: Purpose:: Toxicity: there were no DLTs, but 3 of 11 patients came off study early due to gemcitabine-attributed adverse events (AE). Minimal AEs were attributed to p53MVA vaccination. Immunologic and clinical response: ... ...

    Abstract Purpose:
    Toxicity: there were no DLTs, but 3 of 11 patients came off study early due to gemcitabine-attributed adverse events (AE). Minimal AEs were attributed to p53MVA vaccination. Immunologic and clinical response: enhanced
    MeSH term(s) Adult ; Aged ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/adverse effects ; Cancer Vaccines/immunology ; Cancer Vaccines/therapeutic use ; Carcinoma, Ovarian Epithelial/diagnosis ; Carcinoma, Ovarian Epithelial/immunology ; Carcinoma, Ovarian Epithelial/mortality ; Carcinoma, Ovarian Epithelial/therapy ; Combined Modality Therapy ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Humans ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Platinum/pharmacology ; Platinum/therapeutic use ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Treatment Outcome ; Tumor Suppressor Protein p53/immunology ; Tumor Suppressor Protein p53/metabolism
    Chemical Substances Cancer Vaccines ; MVAp53 vaccine ; Tumor Suppressor Protein p53 ; Deoxycytidine (0W860991D6) ; Platinum (49DFR088MY) ; gemcitabine (B76N6SBZ8R)
    Language English
    Publishing date 2018-01-04
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-17-2709
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Attachment representation and suicidal ideation in Vietnam combat veterans with posttraumatic stress disorder.

    Nye, Ella C / Katzman, Jeffrey / Bell, Jordan B / Kilpatrick, Julie / Brainard, Marythelma / Haaland, Kathleen Y

    Archives of suicide research : official journal of the International Academy for Suicide Research

    2009  Volume 13, Issue 2, Page(s) 195–199

    Abstract: Attachment representation has been linked to psychopathology and suicidality. Possible links between attachment representations and suicidal ideation in a PTSD sample were examined. Vietnam combat veterans in treatment for PTSD (N = 48) were assessed for ...

    Abstract Attachment representation has been linked to psychopathology and suicidality. Possible links between attachment representations and suicidal ideation in a PTSD sample were examined. Vietnam combat veterans in treatment for PTSD (N = 48) were assessed for PTSD severity, attachment representation and current and lifetime suicidality. Contrary to expectation individuals with secure attachment representations had higher levels of current suicidal ideation than those with insecure attachment representations, and unresolved/disorganized attachment was associated with lower levels of current suicidal ideation. Secure attachment may not provide protection against high levels of distress and suicidal ideation among combat veterans with PTSD.
    MeSH term(s) Humans ; Object Attachment ; Prevalence ; Stress Disorders, Post-Traumatic/diagnosis ; Stress Disorders, Post-Traumatic/epidemiology ; Stress Disorders, Post-Traumatic/psychology ; Suicide, Attempted/psychology ; Suicide, Attempted/statistics & numerical data ; Veterans/psychology ; Veterans/statistics & numerical data ; Vietnam Conflict
    Language English
    Publishing date 2009
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 1283671-0
    ISSN 1543-6136 ; 1381-1118
    ISSN (online) 1543-6136
    ISSN 1381-1118
    DOI 10.1080/13811110902835213
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top